HC Wainwright & Co. Reiterates Buy on Crinetics Pharmaceuticals, Maintains $50 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating on Crinetics Pharmaceuticals (NASDAQ:CRNX) and maintained a $50 price target.
March 19, 2024 | 4:24 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. reaffirms a Buy rating on Crinetics Pharmaceuticals with a $50 price target.
The reiteration of a Buy rating and maintenance of a $50 price target by a reputable analyst firm like HC Wainwright & Co. could instill confidence in investors and potentially lead to a positive short-term impact on CRNX's stock price. The specific mention of the company and the reaffirmation of the price target suggest a strong belief in the company's future performance.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100